M-A | Inibidores de aromatase vs. tamoxifeno em mulheres na pré-menopausa com câncer de mama inicial positivo para receptor de estrogênio tratadas com supressão ovariana.

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials – The Lancet Oncology

Comentários:

Aromatase Inhibitors May Benefit Premenopausal Women With Breast Cancer – HealthDay

Aromatase inhibitors are better than tamoxifen at reducing the risk of breast cancer recurrence in premenopausal as well as postmenopausal women – Cancer Research UK